DUBLIN--(BUSINESS WIRE)--The "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 3, 25, 12, 2, 75, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 41 and 7 molecules, respectively.
Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Amyotrophic Lateral Sclerosis - Overview
- Amyotrophic Lateral Sclerosis - Therapeutics Development
- Amyotrophic Lateral Sclerosis - Therapeutics Assessment
- Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
- Amyotrophic Lateral Sclerosis - Drug Profiles
- Amyotrophic Lateral Sclerosis - Dormant Projects
- Amyotrophic Lateral Sclerosis - Discontinued Products
- Amyotrophic Lateral Sclerosis - Product Development Milestones
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/qv86pf/amyotrophic?w=4